Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours
Authors:
- 1 December 2012
- journal article
- research article
- Published by Elsevier in Best Practice & Research Clinical Gastroenterology
- Vol. 26 (6) , 843-854
Abstract
No abstract availableKeywords
This publication has 80 references indexed in Scilit:
- Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine CarcinomasThe Scientific World Journal, 2012
- Evolving Diagnostic and Treatment Strategies for Pancreatic Neuroendocrine TumorsJournal of Hematology & Oncology, 2011
- New Pharmacologic Therapies for Gastroenteropancreatic Neuroendocrine TumorsGastroenterology Clinics of North America, 2010
- Long-term survival after surgical management of neuroendocrine hepatic metastasesHPB, 2010
- The NANETS Consensus Guidelines for the Diagnosis and Management of Poorly Differentiated (High-Grade) Extrapulmonary Neuroendocrine CarcinomasPancreas, 2010
- Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumoursBritish Journal of Cancer, 2010
- O 6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine TumorsClinical Cancer Research, 2008
- TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading systemVirchows Archiv, 2006
- Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?Cancer Chemotherapy and Pharmacology, 2006
- A 5‐decade analysis of 13,715 carcinoid tumorsCancer, 2003